Pr3vent, Inc., a Palo Alto, CA-based healthcare AI company developing machine vision for detecting eye disease in newborns, closed a Series A financing of undisclosed amount.
The round, which followed the seed round announced in October 2018 from Skyview Ventures and Trousdale Ventures, was led by InFocus Capital Partners.
Co-founded in 2017 by noted medical field veterans Jochen Kumm, PhD and Darius M. Moshfeghi, MD, Pr3vent provides an AI-based screening tool designed to protect against vision loss in babies. The company’s technology detects abnormality from non-invasive images of the baby’s retina with an algorithm that instantly identifies pathology and can trigger examination and treatment when it is most effective.
Pr3vent will use the funds to accelerate development of its tool.